Side-by-side comparison of AI visibility scores, market position, and capabilities
Kenvue-owned lactose-free dairy brand with enzyme-treated real milk and ice cream; leading lactase-treated dairy competing with Fairlife and plant-based alternatives for lactose-intolerant consumers.
Lactaid is the leading lactose-free dairy brand, producing milk, ice cream, cottage cheese, and cream products that are treated with lactase enzyme to pre-digest the lactose — allowing the estimated 36% of Americans who are lactose intolerant to enjoy real dairy products without gastrointestinal symptoms. Lactaid is owned by McNeil Nutritionals, a subsidiary of Johnson & Johnson (NYSE: JNJ), though J&J has divested various consumer health assets over the years; the Lactaid brand is now part of the consumer health spinoff Kenvue (NYSE: KVUE).\n\nLactaid's products are made with real cow's milk that undergoes lactase enzyme treatment to break down lactose into simpler sugars (glucose and galactose) that lactose-intolerant individuals can digest without discomfort. The resulting products taste like regular dairy (the additional simple sugars may make the milk slightly sweeter) but are tolerated by those who lack sufficient lactase enzyme production. The Lactaid milk line includes whole, 2%, 1%, fat-free, and calcium-enriched varieties, with the ice cream line as an important premium revenue driver.\n\nIn 2025, Lactaid competes with Fairlife (Coca-Cola, ultra-filtered lactose-free milk), private label lactose-free milk from Horizon Organic (Danone), and plant-based milk alternatives (oat milk, almond milk) that lactose-intolerant consumers may choose instead. Lactaid's brand positioning as real dairy (unlike plant-based alternatives) and its established retail distribution give it a defensible position among lactose-intolerant consumers who prefer dairy taste and nutrition. Kenvue's ownership (post-J&J consumer health spinoff in 2023) provides a dedicated consumer health focus. The 2025 strategy focuses on growing the premium ice cream segment, maintaining retail distribution leadership, and reinforcing the "real dairy, no discomfort" positioning that differentiates Lactaid from both plant-based alternatives and generic lactase supplements.
New York electronic bond trading (NASDAQ: MKTX) $763M FY2024 revenue; Open Trading $2T+ liquidity, 40% US IG bond electronification, portfolio trading growth competing with Tradeweb and Bloomberg.
MarketAxess Holdings Inc. is a New York City-based electronic fixed income trading platform — publicly traded on the NASDAQ (NASDAQ: MKTX) as an S&P 500 Financials component — operating the leading electronic trading marketplace for US investment-grade corporate bonds, US high-yield bonds, emerging market bonds, municipal bonds, and US Treasury securities through approximately 850 employees globally. In fiscal year 2024, MarketAxess reported revenues of $763 million with record trading volumes in US investment-grade bonds and emerging market credit, as the multi-year electronification trend in bond markets continued to shift institutional fixed income trading from voice broker-dealer phone execution to electronic all-to-all trading on MarketAxess's Open Trading marketplace. CEO Chris Concannon (joined 2023, formerly Cboe Global Markets president) leads MarketAxess's strategy of expanding market share beyond the institutional investment-grade core into rate products (US Treasuries, agency securities), high-yield, and portfolio trading as fixed income electronification accelerates — currently approximately 40% of US investment-grade bonds trade electronically versus 15% in 2015. MarketAxess's Open Trading protocol (anonymous all-to-all price discovery between buy-side, sell-side, and market makers) generated over $2 trillion in liquidity provision in 2024, reducing transaction costs versus bilateral dealer quotes by an average of $0.28 per $100 face value.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.